Navigation Links
CutisPharma Announces Issuance of a Patent for Suppository Compounding
Date:11/6/2008

US patent for the preparation, storage, and dispensing of compounded suppositories

WOBURN, Mass., Nov. 6 /PRNewswire/ -- CutisPharma, Inc. today announced that it has received approval from the United States Patent and Trademark Office for its patent (US 7,434,690) regarding a container and kit for the preparation, storage and dispensing of compounded suppositories.

"By its very nature, the process of compounding suppositories is cumbersome, time-consuming and in general, without adequate compensation" said Dr. Indu Muni, founder, chairman, and CEO of CutisPharma, Inc. "Our container (suppository mold) and the method for suppository-compounding is user-friendly and time saving for a pharmacy. Our suppository mold is also customer friendly because the take-home molds are especially designed to not only maintain the integrity of each suppository once compounded, but also provide convenient dispensing tools", he added.

Currently CutisPharma has FIRST(R) Progesterone Vaginal Suppository Unit-of-Use Prescription Compounding Kit product line available, which uses the patented container. The line includes FIRST(R) - Progesterone VGS 25, 50, 100, 200 and 400 representing various strengths (mg.). The kits are made for a single patient and include pre-weighed progesterone, and suppository base, and the patented disposable container/mold for preparation, storage, and dispensing of the suppositories. A single NDC number assigned for the entire kit aids the third party reimbursement process, reduces audit- related adjustments, and the use of these FIRST(R) kits facilitates compliance with USP Chapter <795>. This patented container, kit, and the method will also be used for future suppository compounding kits such as Boric Acid, Morphine, and others.

CutisPharma estimates that over 1.5 million progesterone suppository prescriptions are written in the U.S. annually, representing a potential of nearly $100 million at the retail level. The Kit allows a pharmacy an easy entry into this market. The Company is experiencing a steady conversion from the conventional way to the FIRST(R) - way.

FIRST(R) products save dispensing time, are easy to use, and can be compounded by the pharmacist while the patient waits increasing customer satisfaction. Using FIRST(R) VGS kits, the pharmacist can compound a prescription for 30 vaginal suppositories 4 to 5 times faster than those prepared by the traditional method using a metal suppository mold or polystyrene shells.

About CutisPharma

CutisPharma, Inc. based in Woburn, MA, is a privately held, specialty pharmaceutical company focusing on developing and commercializing value-added proprietary drug products and technologies in the prescription compounding sector of the pharmaceutical industry. Product line and development efforts, initially are focused on providing optimized, more efficient alternatives for the preparation of the nearly 8 million currently compounded prescriptions, by offering FIRST(R) Unit-of-Use Prescription Compounding Kits. Use of these branded compounding kits will be beneficial to all triad participants, namely physicians, pharmacists, and patients. Two U.S. patents have been issued to the Company with several additional patents pending.

For more information please visit our website at http://www.cutispharma.com/


'/>"/>
SOURCE CutisPharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. CutisPharma Announces Strategic Collaboration with Rite Aid Corporation
2. CutisPharma Selected by Medicine Shoppe International as Preferred Vendor for Unit-of-Use Compounding Kits
3. Stereotaxis Announces New Management Appointment
4. SXC Health Solutions announces third quarter financial results
5. 360 Healthcare Staffing Announces Agreement With BlueSky Medical Staffing Software
6. Cardinal Health Announces Preliminary Shareholder Voting Results at Annual Meeting
7. Dialysis Corporation of America Announces $25 Million Credit Facility
8. Cornerstone Therapeutics Announces New Board of Directors
9. CardiacAssist, Inc. Announces Record Breaking Site Activity and Financial Results
10. BD Announces Executive Appointments of President and Chief Financial Officer
11. BD Announces Results for Fourth Fiscal Quarter and Full Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, ... Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility ... home to some of the world’s leading providers of cereal and other breakfast foods. ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many ... been diagnosed with endometriosis. These women need a treatment plan to not only ... approach that can help for preservation of fertility and ultimately achieving a pregnancy. ...
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health ... of their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards ... at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology ... outcomes platform, Bracket eCOA (SM) 6.0, at the 52 ... 30, 2016 in Philadelphia , Pennsylvania.  A ... product of its kind to fully integrate with RTSM, will ... 6.0 is a flexible platform for electronic clinical outcomes assessments ...
Breaking Medicine Technology: